Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZFHX4 antisense RNA 1 (ZFHX4-AS1) is a long non-coding RNA located on chromosome 8q21.13[1]. It does not encode a protein but functions as an antisense transcript for the ZFHX4 gene, modulating the expression of sense mRNA through RNA-RNA interactions[2]. ZFHX4-AS1 is aberrantly upregulated in several types of human cancer, including adrenocortical carcinoma, ovarian cancer, breast cancer, gastric cancer, and glioma[1][3][4]. Biological studies indicate that ZFHX4-AS1 promotes cancer cell proliferation, migration, and invasion, possibly through competing endogenous RNA (ceRNA) networks and by regulating pathways related to cell cycle and metastasis[1][3]. High expression of ZFHX4-AS1 is correlated with poorer prognosis in multiple cancers and has potential as a prognostic biomarker and a therapeutic target, especially in adrenocortical carcinoma and ovarian cancer, but it is not currently a direct therapeutic target with known drugs[1][3][4]. There is no evidence of direct safety concerns or currently approved drugs specifically targeting this lncRNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZFHX4 antisense RNA 1 (ZFHX4-AS1).